NOVEL DRUG FOR THE IMMUNOTHERAPY OF HIV/
HIV / AIDS is a globally dreaded viral plague. The maternal morbidity and child mortality is worrisome , most especially in sub Saharan Africa. The available anti retroviral drugs are usually combined before the effect can be felt on the victim temporarily. The chemically formulated anti retroviral drugs have side effects, thereby increasing the viral drug resistance globally. The innovative solution to this global challenge is the discovery of a potent novel drug for the treatment of HIV / AIDS.
Novel drug for the treatment of HIV / AIDS with mobile authentication mechanism.
Novel drug for the treatment of HIV / AIDS with mobile authentication mechanism.
All victims , carriers and patients of HIV / AIDS globally.
Solution to global challenge on health , specifically HIV / AIDS.
- Prototype: A venture or organization building and testing its product, service, or business model
- A new business model or process
Presently , there is no drug for the treatment of HIV / AIDS globally. This novel drug for the treatment of HIV / AIDS will break a global record.
Mobile authentication mechanism
TESTED & TRUSTED : (see the attachment)
- Biotechnology / Bioengineering
- Software and Mobile Applications
Data collected from 90 different ethno botanists in different states of Nigeria indicate clearly that the synergized bioactive ingredients have been used to cure HIV / AIDS for many years. Therefore , this synergized green drug has been tested and trusted.
- Women & Girls
- Pregnant Women
- Infants
- Children & Adolescents
- Elderly
- Persons with Disabilities
- 3. Good Health and Well-Being
- 9. Industry, Innovation, and Infrastructure
- Nigeria
- United Kingdom
- United States
The solution is expected to benefit about one hundred million people globally.
Well established global solution finder and innovator
Grant / Funding
Seeking for grants or financial assistance.
- Nonprofit
N / A
Full time staff=2. , Part time staff=10. , Contractors=3. ,
2 experienced professors of toxicology and pharmacy respectively , 2 Senior technologists and Senior academics.
N / A
The customers are the victims or patients , as well as the carriers globally. This drug is expected to generate millions of US Dollars globally , after clinical trials.
- Individual consumers or stakeholders (B2C)
Combination of grants and funding. Selling of the products will also make money available.
Grant , Collaboration , Partnership.
- Funding and revenue model
- Marketing, media, and exposure
- Other
Grants for research purposes, partnership and collaboration for clinical trials.
MIT faculty as well as investors
Engr.